Scarica l'app Stockscreener
36.71
1.55%
0.56
Dopo l'orario di chiusura:
37.44
0.73
+1.99%
Precedente Chiudi:
$36.15
Aprire:
$35.9
Volume 24 ore:
207.49K
Relative Volume:
0.64
Capitalizzazione di mercato:
$1.75B
Reddito:
-
Utile/perdita netta:
$-111.48M
Rapporto P/E:
-12.81
EPS:
-2.865
Flusso di cassa netto:
$-88.09M
1 W Prestazione:
+8.96%
1M Prestazione:
+31.86%
6M Prestazione:
+42.40%
1 anno Prestazione:
+282.40%
Intervallo 1D:
$35.41
$36.99
Intervallo di 1 settimana:
$33.18
$36.99
Portata 52W:
$7.73
$42.27
Rapport Therapeutics Inc Stock (RAPP) Company Profile
Nome
Rapport Therapeutics Inc
Settore
Industria
Telefono
857-321-8020
Indirizzo
99 HIGH STREET, BOSTON
Compare RAPP vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RAPP
Rapport Therapeutics Inc
|
36.71 | 1.73B | 0 | -111.48M | -88.09M | -2.865 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Rapport Therapeutics Inc Stock (RAPP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-10 | Iniziato | Raymond James | Strong Buy |
| 2026-02-02 | Iniziato | Wells Fargo | Overweight |
| 2025-11-19 | Iniziato | BTIG Research | Buy |
| 2025-09-16 | Iniziato | Truist | Buy |
| 2025-08-06 | Iniziato | H.C. Wainwright | Buy |
| 2025-04-08 | Iniziato | Citizens JMP | Mkt Outperform |
| 2024-07-02 | Iniziato | Jefferies | Buy |
| 2024-07-02 | Iniziato | Stifel | Buy |
| 2024-07-02 | Iniziato | TD Cowen | Buy |
Mostra tutto
Rapport Therapeutics Inc Borsa (RAPP) Ultime notizie
(RAPP) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Insider Sell: Krishnaswamy Yeleswaram Sells Shares of Rapport Th - GuruFocus
Rapport Therapeutics Insider Sold Shares Worth $695,823, According to a Recent SEC Filing - marketscreener.com
10b5-1 insider sales reported for RAPP (NASDAQ: RAPP) in March–April 2026 - Stock Titan
Is Rapport Therapeutics Inc undervalued by DCF analysis2026 Pullbacks & Reliable Price Breakout Alerts - baoquankhu1.vn
How Investors May Respond To Rapport Therapeutics (RAPP) Phase 2a RAP-219 Data Spotlight At AAN 2026 - simplywall.st
Form 144 shows proposed 500-share sale; insider 10b5-1 trades (RAPP) - Stock Titan
Rapport Therapeutics’ Yeleswaram sells $12.6k in stock By Investing.com - Investing.com India
Insider Sell: Krishnaswamy Yeleswaram Sells Shares of Rapport Therapeutics Inc (RAPP) - GuruFocus
Rapport Therapeutics’ Yeleswaram sells $12.6k in stock - Investing.com
Rapport Therapeutics (RAPP) CDO sells small block of shares - Stock Titan
Risk Report: Is Rapport Therapeutics Inc gaining market shareEarnings Recap Summary & AI Enhanced Trading Signals - baoquankhu1.vn
Form 144: Morgan Stanley Smith Barney (NASDAQ: RAPP) lists 360-share sale - Stock Titan
Bond Watch: What hedge funds are buying Rapport Therapeutics Inc2026 Earnings & Low Risk Profit Maximizing Plans - baoquankhu1.vn
Earnings Risk: What are Rapport Therapeutics Incs technical support levels2026 Spike Watch & Fast Entry and Exit Trade Plans - baoquankhu1.vn
(RAPP) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Rapport Therapeutics, Inc. (NASDAQ:RAPP) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Is Rapport Therapeutics (RAPP) Turning Its TARPγ8 Precision Seizure Program Into a Scalable Platform? - simplywall.st
Rapport Therapeutics, Inc. (RAPP) Stock Price, News, Quote & History - Yahoo! Finance Canada
Rapport Therapeutics to present epilepsy trial data at AAN By Investing.com - Investing.com South Africa
Rapport Therapeutics to Present New Phase 2 Treatment Follow-Up Data for RAP-219 in Focal Onset Seizures at the 2026 American Academy of Neurology Annual Meeting - Sahm
Rapport Therapeutics to present epilepsy trial data at AAN - Investing.com
Rapport's new 8-week seizure data heads to a major neurology meeting - Stock Titan
Market Catalysts: Is Rapport Therapeutics Inc a good stock for dollar cost averaging2026 Growth vs Value & Risk Adjusted Buy and Sell Alerts - baoquankhu1.vn
Rapport Therapeutics COO Gault sells $281k in stock By Investing.com - Investing.com Canada
Rapport Therapeutics COO Gault sells $281k in stock - investing.com
Rapport Therapeutics Insider Sold Shares Worth $281,857, According to a Recent SEC Filing - marketscreener.com
Rapport Therapeutics (RAPP) COO sells 10,000 shares under Rule 10b5-1 plan - Stock Titan
10,000-share Rule 144 sale by RAPP (NASDAQ: RAPP) lists $278,400 value - Stock Titan
Patterns Watch: What is the cash position of Rapport Therapeutics IncMarket Sentiment Review & Fast Exit and Entry Trade Guides - baoquankhu1.vn
Aug Ideas: What hedge funds are buying Rapport Therapeutics Inc2026 Earnings & Fast Exit and Entry Trade Guides - baoquankhu1.vn
Will Rapport Therapeutics Inc benefit from AI trendsPortfolio Gains Summary & Risk Controlled Swing Alerts - baoquankhu1.vn
Will Rapport Therapeutics' RAP-219 Deliver A Pipeline-in-a-Product Story? - RTTNews
Rapport Therapeutics (NASDAQ:RAPP) Raised to “Strong-Buy” at Truist Financial - defenseworld.net
Yeleswaram, Rapport Therapeutics chief development officer, sells $303k By Investing.com - Investing.com India
Yeleswaram, Rapport Therapeutics chief development officer, sells $303k - Investing.com
Rapport Therapeutics Insider Sold Shares Worth $303,355, According to a Recent SEC Filing - MarketScreener
Rapport Therapeutics (RAPP) CDO sells 10,115 shares under 10b5-1 plan - Stock Titan
All you need to know about Rapport Therapeutics, Inc. (RAPP) rating upgrade to buy - MSN
All Essential Information Regarding Rapport Therapeutics, Inc. (RAPP) Rating Raised to Buy - Bitget
All You Need to Know About Rapport Therapeutics, Inc. (RAPP) Rating Upgrade to Buy - sharewise.com
Rapport Therapeutics (NASDAQ:RAPP) Upgraded at Truist Financial - MarketBeat
RAPP (NASDAQ: RAPP) insider sale reported: 2,840 common shares - Stock Titan
Geopolitics Watch: Will Rapport Therapeutics Inc stock go up in YEAR2026 Price Targets & AI Driven Price Predictions - baoquankhu1.vn
(RAPP) Risk Channels and Responsive Allocation - Stock Traders Daily
RAPP SEC FilingsRapport Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
RAPP Earning Date, Earning Analysis and Earning Prediction - intellectia.ai
How Investors May Respond To Rapport Therapeutics (RAPP) Licensing RAP-219 To Tenacia In Greater China - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Immutep Ltd (OtherPRRUF), Coya Therapeutics, Inc. (COYA) and Rapport Therapeutics, Inc. (RAPP) - The Globe and Mail
Aug Selloffs: Why is Rapport Therapeutics Inc stock going up2026 Trends & Scalable Portfolio Growth Ideas - baoquankhu1.vn
Buyout Rumor: Does Rapport Therapeutics Inc have strong fundamentals2026 Highlights & Long-Term Capital Growth Strategies - baoquankhu1.vn
Rapport Therapeutics Inc Azioni (RAPP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.69%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):